FDA Panel Votes Against Arena's Diet Drug
September 16, 2010
Another diet drug, Arena Pharmaceuticals's Iorcaserin, appears to be in danger after a U.S. Food and Drug Administration advisory panel voted to reject it Thursday. Continue reading FDA Panel Votes... Read More
from DailyFinance.com
FDA Panel Rejects Arena's Lorqess
September 16, 2010
Orexigen Therapeutics (OREX) Rips Higher After Arena's Failure
September 16, 2010
Orexigen (OREX), VIVUS (VVUS) Shares Spike Higher as FDA Panel Won't Back Arena's (ARNA) Lorcaserin
September 16, 2010
Arena (ARNA) Fails to Win Backing of FDA Panel for Lorcaserin Diet Pill
September 16, 2010
Arena, Orexigen in spotlight; drug indexes dip
September 16, 2010
Rivals Orexigen Therapeutics and Arena Pharmaceuticals are in the spotlight as a Food and Drug Administration advisory panel convenes to consider whether to recommend Arena’s diet-drug lorcaserin for... Read More
from MarketWatch
Canaccord Genuity on Life Sciences/Biotechnology: Takeaways from the Sibutramine Panel
September 16, 2010
Orexigen (OREX) and VIVUS (VVUS) Expected To See Volatility Due to Arena's (ARNA) FDA Panel Meeting
September 16, 2010
UPDATE 1-Arena defends diet drug safety to U.S. panel
September 16, 2010
* Analysts expect peak sales of $822 million if approved (Rewrites, adds start of meeting, company comments) Read More
category
companyNews
Vivus (VVUS) volatility flat at 119
September 16, 2010
FDA to Review Arena's Diet Drug, Alkermes' Painkiller Addiction Med
September 16, 2010
It's a busy day at the FDA today as panels meet to discuss two new drugs -- one to help weight loss and the other to combat drug addiction -- and decide whether to approve AstraZeneca's new blood... Read More
from DailyFinance.com
New diet drug faces U.S. advisers amid risk debate
September 16, 2010
ADELPHI, Md., Sept 16 (Reuters) - Arena Pharmaceuticals Inc faces a pivotal test on Thursday as U.S. government advisers consider whether to back the company's weight-loss pill amid questions about... Read More
category
companyNews
Arena's Big Day Looms Large (ARNA, VVUS, OREX)
September 15, 2010
FACTBOX-Timeline and facts about obesity drugs
September 15, 2010
WASHINGTON, Sept 15 (Reuters) - An advisory panel that met Wednesday was evenly divided on whether a weight-loss drug from Abbott Laboratories was too dangerous to stay on the market. [ID:nN15144589] Read More
category
companyNews
UPDATE 1-Abbott defends diet drug in fight for U.S. market
September 15, 2010
* Outside FDA panel meets Thursday on Arena rival (Recasts paragraph 1, adds Abbott comment, updates shares) Read More
category
companyNews
Abbott diet drug faces US fight to stay on market
September 15, 2010
WASHINGTON, Sept 15 (Reuters) - Amid a battle to reshape the nearly $400 million obesity drug sector, Abbott Laboratories faces a critical test on Wednesday over whether its controversial diet pill... Read More
category
companyNews
Arena's Stock Nosedives on Negative FDA Briefing Documents
September 14, 2010
Wedbush Says Arena (ARNA) News is Not New; Recommends Buying VIVUS (VVUS) on 'Any Sympathetic Weakness'
September 14, 2010
Arena, Icagen plunge; drug indexes climb
September 14, 2010
Arena Pharmaceuticals Inc. and Icagen Inc. are the notable standouts, sinking as the drug sector’s two main indexes climb into positive territory. Read More
from MarketWatch
UPDATE 2-FDA staff question Arena diet drug, shares plunge
September 14, 2010
category
companyNews
Why You Should Pay Attention to Arena's Lorquess
September 10, 2010
Why You Should Pay Attention to Arena's Lorqess
September 10, 2010
Wall Street Hubbub 9/10: Computer Sciences (CSC) Seen As Great LBO Target, China-Biotics (CHBT) Addresses "Rumors", Hartford Financial (HIG) Up on Buyout Chatter
September 10, 2010
FACTBOX-Timeline and facts about obesity drugs
September 09, 2010
WASHINGTON, Sept 9 (Reuters) - Three new weight-loss drugs are up for Food and Drug Administration review this year. One is Arena Pharmaceuticals Inc's candidate Lorqess or lorcaserin, the focus of a... Read More
category
companyNews
BofA/Merrill Starts Orexigen (OREX) at Neutral, Arena (ARNA), VIVUS (VVUS) at Underperform
September 08, 2010
Orexigen Finds A Cautious Partner (SNY, RHHBY, ABT, OREX, ARNA, VVUS)
September 03, 2010
Upbeat Jobs Report Lifts Markets To Higher Open
September 03, 2010
Private employers added more jobs than expected in August to lift the markets to a higher open with Dow climbing 83 points to 10,404. Nasdaq gained 23 points to 2224. Read More
category
Market News
Vivus (VVUS) Is One of Today's Top Gainers, Up 11.5%
September 02, 2010
Vivus (VVUS) leads the list of top gainers so far today and is now at $6.38, up $0.66 (11.56%) on volume of 3,950,017 shares traded. Over the last 52 weeks ...(Click the story link or go to... Read More
category
VVUS
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here